Scope of the seat
The Independent Director will bring operating and stakeholder judgement to a Board governing pharmaceutical research, manufacturing, regulated-market access and commercial portfolios. As Chair of the Nomination and Remuneration Committee and Stakeholders Relationship Committee, with membership of the Audit Committee, the appointee must be able to connect leadership, conduct, product responsibility and financial consequence.
The role is designed for an experienced pharmaceutical, healthcare, regulatory, commercial or enterprise leader. It does not require the Director to second-guess scientific or medical specialists. It does require the ability to test whether expert conclusions are supported, whether disagreements are escalated, and whether incentives permit inconvenient evidence to reach the Board.
Leadership succession where judgement is non-delegable
The NRC will assess the succession and performance of the chief executive and leaders responsible for research, medical affairs, quality, manufacturing, regulatory affairs, pharmacovigilance, supply, commercial markets and finance. These positions cannot be evaluated on functional targets alone; failure at their boundaries is often where the largest exposure accumulates.
The Chair will insist that succession candidates have been tested in situations involving product quality, regulator engagement, constrained supply, portfolio discontinuation, adverse evidence or a difficult market decision. High performance in stable conditions does not establish readiness for enterprise leadership.
Critical-person risk will be examined across scientific, technical and regulatory roles as well as the executive committee. The organisation should know where knowledge resides in one individual, where a release or submission depends on a fragile team, and where external advisers are substituting for institutional capability.
Incentives must preserve the right to stop
Discovery milestones, filing targets, launch dates, capacity utilisation, market share and sales can all create pressure to reinterpret weak evidence. The Director will review whether performance measures preserve the authority to pause a study, reject a batch, defer a filing, correct a claim or recall a product without destroying an individual’s career for doing the right thing.
Variable pay will balance commercial performance with quality, regulatory outcomes, patient safety, supply continuity, working capital and leadership behaviour. The committee should be able to apply downward adjustment where an outcome was achieved by accumulating a risk that emerged later.
Leadership assessment will consider the treatment of dissent. A company that celebrates scientific challenge but punishes operating challenge does not have a speak-up culture.
Stakeholder relationships in a high-consequence industry
The Stakeholders Relationship Committee will oversee more than investor-service metrics. Its agenda should integrate investors, patients, healthcare professionals, employees, regulators, distributors, research partners and communities where a material grievance may expose a wider weakness.
The Chair will require clear routes for adverse-event information, product complaints, medical-information requests, access concerns, distributor conduct, data corrections and investor grievances. Case closure must record remedy, root cause, trend and accountable prevention. Cases involving patient harm, regulatory reporting, misleading claims or retaliation must reach the appropriate Board forum quickly.
Public and investor communication about pipeline progress, approvals, shortages, remediation and market opportunity must preserve uncertainty. The Director will challenge disclosures that are literally accurate but create a stronger impression than the evidence supports.
The Audit Committee connection
As an Audit Committee member, the Director will focus on estimates and transactions whose accounting depends on scientific, regulatory or commercial judgement. These may include development expenditure, impairment, inventory expiry, product returns, chargebacks, rebates, litigation, regulatory remediation, contract manufacturing, licensing milestones and contingent consideration.
Management papers should show the underlying evidence, alternative interpretation and sensitivity—not only the preferred conclusion. Internal audit should test data lineage and decision controls across laboratories, plants, regulatory systems, safety systems, distributors and finance.
The Director will also examine whether quality and regulatory observations are translated into provisions, capacity decisions and forecast risk in a timely way. A remediation plan that exists outside the financial plan is not fully governed.
Portfolio choices and Board debate
Although this is not designated as a strategy-committee seat, the Director will contribute to portfolio decisions. The Board should understand the differentiated patient need, evidence burden, development and manufacturing dependency, commercial pathway, cash requirement and downside trigger for each material programme.
The appointee will press for explicit stop, partner or redesign criteria. Persistence is not a strategy when new evidence has changed the probability, economics or risk of success.
First six months
The incoming Director should complete structured sessions with committee chairs, auditors and leaders across quality, regulatory, medical, manufacturing, commercial and finance. Early committee work will include a leadership-depth review, a remuneration-risk test, a stakeholder escalation map and one joined-up examination of a product or market where scientific, quality, commercial and accounting judgements intersect.
Candidate profile
Applicants should have at least twenty years of senior experience in pharmaceuticals, healthcare, life sciences or a tightly regulated adjacent industry. Relevant backgrounds include enterprise leadership, regulated-market commercial responsibility, manufacturing and quality leadership, medical or regulatory affairs, finance, public policy or institutional stakeholder management.
Prior Board or committee-chair experience is strongly preferred. Applications should set out IICA Databank status, DIN (if held), regulated-industry exposure, committee history, conflicts and a concise example of a decision where protecting evidence or stakeholder trust required resisting a powerful commercial timetable.
Registration on the IICA Independent Directors Databank is required before appointment. A DIN is not needed to apply: where an appointee does not yet hold one, it is obtained through the appointing company at the point of appointment.